HKD 0.13
(-2.31%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 675.58 Million HKD | -19.04% |
2022 | 834.5 Million HKD | -21.99% |
2021 | 1.06 Billion HKD | 31.21% |
2020 | 815.29 Million HKD | 2.92% |
2019 | 792.16 Million HKD | 222.37% |
2018 | 245.73 Million HKD | -25.61% |
2017 | 330.33 Million HKD | 89.31% |
2016 | 174.49 Million HKD | -44.1% |
2015 | 312.13 Million HKD | -43.56% |
2014 | 553 Million HKD | 133.15% |
2013 | 237.18 Million HKD | 94.36% |
2012 | 122.03 Million HKD | 218.02% |
2011 | 38.37 Million HKD | 40.48% |
2010 | 27.31 Million HKD | -82.56% |
2009 | 156.62 Million HKD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 Q4 | 675.58 Million HKD | 0.0% |
2023 FY | 675.58 Million HKD | -19.04% |
2023 Q2 | 792.71 Million HKD | 0.0% |
2022 Q4 | 834.5 Million HKD | 0.0% |
2022 FY | 834.5 Million HKD | -21.99% |
2022 Q2 | 984.35 Million HKD | 0.0% |
2021 Q2 | 918.74 Million HKD | 0.0% |
2021 Q4 | 1.06 Billion HKD | 0.0% |
2021 FY | 1.06 Billion HKD | 31.21% |
2020 FY | 815.29 Million HKD | 2.92% |
2020 Q2 | 777.28 Million HKD | 0.0% |
2020 Q4 | 815.29 Million HKD | 0.0% |
2019 FY | 792.16 Million HKD | 222.37% |
2019 Q4 | 792.16 Million HKD | 0.0% |
2019 Q2 | 233.53 Million HKD | 0.0% |
2018 FY | 245.73 Million HKD | -25.61% |
2018 Q4 | 245.73 Million HKD | 0.0% |
2018 Q2 | 391.27 Million HKD | 0.0% |
2017 FY | 330.33 Million HKD | 89.31% |
2017 Q4 | 330.33 Million HKD | 0.0% |
2017 Q2 | 318.71 Million HKD | 0.0% |
2016 Q4 | 174.49 Million HKD | 0.0% |
2016 FY | 174.49 Million HKD | -44.1% |
2016 Q2 | 175.54 Million HKD | 0.0% |
2015 FY | 312.13 Million HKD | -43.56% |
2015 Q2 | 600.67 Million HKD | 0.0% |
2015 Q4 | 312.13 Million HKD | 0.0% |
2014 Q4 | 553 Million HKD | 0.0% |
2014 FY | 553 Million HKD | 133.15% |
2014 Q2 | 461.84 Million HKD | 0.0% |
2013 Q2 | 190.42 Million HKD | 0.0% |
2013 FY | 237.18 Million HKD | 94.36% |
2013 Q4 | 237.18 Million HKD | 0.0% |
2012 Q3 | 118.08 Million HKD | 19.01% |
2012 Q4 | 122.03 Million HKD | 3.34% |
2012 Q1 | 95.56 Million HKD | 149.03% |
2012 Q2 | 99.22 Million HKD | 3.83% |
2012 FY | 122.03 Million HKD | 218.02% |
2011 FY | 38.37 Million HKD | 40.48% |
2011 Q2 | 15.45 Million HKD | 0.0% |
2011 Q4 | 38.37 Million HKD | 0.0% |
2010 Q4 | 27.31 Million HKD | 0.0% |
2010 FY | 27.31 Million HKD | -82.56% |
2010 Q2 | 72.31 Million HKD | 0.0% |
2009 Q4 | 156.62 Million HKD | 0.0% |
2009 FY | 156.62 Million HKD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Natural Beauty Bio-Technology Limited | 308.05 Million HKD | -119.303% |
Innovative Pharmaceutical Biotech Limited | 1.06 Billion HKD | 36.481% |
China Overseas Nuoxin International Holdings Limited | 109.1 Million HKD | -519.226% |
Prosperous Future Holdings Limited | 177.1 Million HKD | -281.45% |
Fourace Industries Group Holdings Limited | 61.8 Million HKD | -993.086% |
Evergreen Products Group Limited | 786.46 Million HKD | 14.099% |
EC Healthcare | 2.97 Billion HKD | 77.255% |
Ming Fai International Holdings Limited | 772.01 Million HKD | 12.491% |
Blue Moon Group Holdings Limited | 1.61 Billion HKD | 58.242% |
SuperRobotics Holdings Limited | 172.27 Million HKD | -292.16% |
Takbo Group Holdings Limited | 42.84 Million HKD | -1476.658% |
Hyfusin Group Holdings Limited | 181.34 Million HKD | -272.533% |